Proving the Diagnosis: Tests and Pathology Reports

Getting to a definitive diagnosis of Autosomal Recessive Congenital Sideroblastic Anemia (ARCSA) requires more than just a standard blood test. Because this condition is so rare and can look like other types of anemia, your medical team must follow a specific diagnostic path that combines high-tech microscopic imaging with advanced genetic sequencing ^[1][2].

The Bone Marrow Evidence

The first major step toward a diagnosis usually involves a bone marrow aspirate. While a biopsy looks at the structure of the bone marrow, an aspirate allows doctors to look closely at individual developing cells (called erythroblasts).

To find sideroblasts, a pathologist uses a special dye called a Prussian blue stain (also known as a Perls stain) ^[1][3]. This stain highlights iron in a vivid blue color. In a healthy cell, iron is scattered or invisible. In ARCSA, the iron is trapped in the mitochondria of these bone marrow precursors, which sit in a circle around the cell’s nucleus. Under the microscope, this looks like a “ring” or a “pearl necklace” made of blue dots ^[1][4].

• The 15% Rule: For a diagnosis of acquired sideroblastic anemia, at least 15% of the developing red blood cells (erythroblasts) must be “ring sideroblasts” ^[5][6]. While this threshold is common for classifying acquired conditions, it is not a strict, universal requirement for diagnosing congenital inherited forms, where the percentage is interpreted in context.
• Defining a Ring Sideroblast: Not every cell with iron is a ring sideroblast. Doctors specifically look for cells where the blue iron granules cover at least one-third of the nucleus’s circumference, typically defined as at least five iron granules ^[1].

Why Microscopic Evidence Is Not Enough

Seeing ring sideroblasts is evidence of the disease, but it doesn’t tell the doctor why it is happening. Ring sideroblasts can appear in many different conditions, including:

• Acquired causes: Lead poisoning, copper deficiency, or certain medications ^[2][3].
• MDS: Myelodysplastic syndromes, which are more common in adults but can occur in children. MDS is diagnosed by integrating morphology, cytogenetics, and clinical context, often alongside mutations in a gene called SF3B1 ^[5][7].
• Other Genetic Forms: The X-linked version (ALAS2) can look identical under a microscope to the autosomal recessive version (SLC25A38) ^[7][8].

The Recommended Role of Genetic Testing

Because treatment and the risk for future children depend entirely on the specific gene involved, genetic testing is strongly recommended ^[2][9]. Your team will likely use a targeted gene panel or Whole Exome Sequencing (WES) to look for variants in genes like SLC25A38 (the most common recessive cause) or others like GLRX5 and HSPA9 ^[10][9][11].

This testing helps confirm the condition is autosomal recessive by showing that the child has two pathogenic variants—one inherited from each parent. This is called being “in trans” ^[12][13]. However, keep in mind that a negative genetic panel does not entirely rule out a congenital cause, as some variants are difficult to detect or remain undiscovered.

Completeness Checklist for Your Records

When you receive your child’s medical reports, ensure the following data points are included. If they are missing, you should ask your hematologist for clarification, as pathogenicity and phase must be interpreted by a genetics professional.

Pathology Report (Bone Marrow)

• [ ] Aspirate Quality: Confirmation that the sample was “adequate” for review.
• [ ] Stain Method: Mention of Prussian blue or Perls stain ^[1].
• [ ] Percentage of Ring Sideroblasts: Must be quantified ^[5].
• [ ] Iron Grade: A qualitative score describing the total iron stores ^[14].
• [ ] Dysplasia: Notes on whether other cells (like white blood cells or platelets) look abnormal.

Genetic Testing Report

• [ ] Specific Gene: The name of the mutated gene (e.g., SLC25A38) ^[10].
• [ ] Variant Classification: Whether the variant is classified as “Pathogenic,” “Likely Pathogenic,” or a “Variant of Uncertain Significance” ^[13].
• [ ] Zygosity: Whether the child has two variants (homozygous or compound heterozygous) ^[12].
• [ ] Transcript Version: The specific “version” of the genetic code used for comparison (e.g., NM_017875.4) ^[12].
• [ ] Parental Testing: Confirmation that both parents were tested to see if they are carriers ^[15].